Fri, Jul 11, 2014, 7:16 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Microsoft Corporation Message Board

lws2000 726 posts  |  Last Activity: 2 hours 39 minutes ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • lws2000 lws2000 2 hours 39 minutes ago Flag

    The controlled channel is still with us ($2.80 to $3.20) as we closed @ $3.00 . The release of the Mayo hold moved us from the $2 channel to the $3 channel. Geron is a coiled spring that is about to be released. Mayo will see to that. The channel manipulation is about to end; we all sense that, even the shorts. Imetelstat is just too good to be held back much longer.

  • I think we are saying the same thing. Mayo is the father, and Geron is the son. Mayo has the experience and wisdom, while Geron is still wet behind the ears, but learning.

  • The hold now seems unnecessary. The fact that the Mayo hold has been lifted and the Geron hold has not, says something about the credibility, size, age, and stability of Mayo vs. Geron. Geron is barely a teenager trying to find its proper place in this world, while Mayo, the old sage, points to the road that needs to be traveled. The FDA is favoring Mayo, but Geron is not too far behind. Imetelstat is a gift to all (Mayo, Geron, researchers, patients).

  • lws2000 lws2000 Jul 8, 2014 8:04 PM Flag

    JUST REMEMBER: "Tantamount to a cure". This is a solid review, and it is all positive. The world is listening, and the FDA is listening. Nobody has any significant negatives (medicine & science).
    ***********************************************************
    FROM MAYO BROCHURE:

    At Mayo Clinic, discoveries happen every day. We focus on the needs of the patient, which require that our research model addresses patient-centered, patient-inspired discoveries.

    STOPPING HEMATOLOGICAL CANCER: New Drug Induces Remissions in Myelofibrosis

    The results of a Mayo Clinic study demonstrate that a drug named imetelstat induces remissions in some patients with myelofibrosis. This is a form of chronic leukemia that affects the patient’s bone marrow that is replaced by fibrosis (scar tissue) instead of blood-producing cells.

    Scientists do not yet know the exact mechanism of action for imetelstat, but believe it interferes with the survival and proliferation of cancer cells by inhibiting a critical enzyme called telomerase. One of the functions of telomerase is to repair the ends of chromosomes called telomeres, and because cancer cells have shorter than normal telomere size, they are particularly susceptible to the drug.

    The study results are promising. Some patients participating in the clinical trial taking imetelstat obtained dramatic responses, and we have seen some complete responses (tantamount to a cure), which is almost unheard of in this disease.

    Although patients may experience relief in response to other treatments, their bone marrow does not usually return to normal. But in the case of this new therapy, some of the patients participating in the trial developed normal bone marrow.

    Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for more than six months. Among these 22 patients, two achieved complete remissions and three partial remission, including reversal of bone marrow fibrosis in four of the five.

  • This is a contest for the ages, and a good subject for a PhD thesis. There are numerous subplots here. IMO, the "Miracle Drug" ultimately dominates, but the market control has been amazing. There seems to be something unusual going on, that is beyond normal market interactions. Mayo has told the whole world, loud and clear in their current brochure, that Imetelstat is the "real-thing". The FDA has to be listening, and has no reason to oppose Mayo's very carefully acquired results in their MF trials and studies.

  • lws2000 lws2000 Jul 8, 2014 1:54 PM Flag

    The Challenge has not been met. The Conclusion is that there is no public information that opposes the use of Imetelstat, and that the FDA is prepared to fully back it, with proper data gathering.

  • The challenge is to show any creditable science or medical results that negatively effect Imetelstat. There appears to be none. Mayo is now promoting Imetelstat in its new brochure, which also benefits Geron.

    I have to stay very upbeat, since all the science (including Nobel Prize), and all of the medicine (trails, remissions, "tantamount to a cure") are positive. Unless there is a negative story that someone can find, everything is positive. My conclusion is Mayo and the FDA are working closely together, with Geron's blessing. Mayo has a long and trusted history. The FDA has and will continue to listen to and believe Mayo.

    Science and sound medicine have already turned the corner for Imetelstat's success (treatment & pipeline). No one can post any negative information. Seeking Alpha is correct; Geron stock price will explode to the upside. Surprises are coming soon, IMO, but I am prepared to wait.

  • At Mayo Clinic, discoveries happen every day. We focus on the needs of the patient, which require that our research model addresses patient-centered, patient-inspired discoveries.

    STOPPING HEMATOLOGICAL CANCER: New Drug Induces Remissions in Myelofibrosis

    The results of a Mayo Clinic study demonstrate that a drug named imetelstat induces remissions in some patients with myelofibrosis. This is a form of chronic leukemia that affects the patient’s bone marrowthat is replaced by fibrosis (scar tissue) insteadof blood-producing cells.

    Scientists do not yet know the exact mechanism ofaction for imetelstat, but believe it interferes with the survival and proliferation of cancer cells by inhibitinga critical enzyme called telomerase. One of the functionsof telomerase is to repair the ends of chromosomes called telomeres, and because cancer cells have shorter than normal telomere size, they are particularly susceptibleto the drug.

    The study results are promising. Some patients participating in the clinical trial taking imetelstat obtaineddramatic responses, and we have seen some complete responses (tantamount to a cure), which is almost unheard of in this disease.

    Although patients may experience relief in responseto other treatments, their bone marrow does not usually return to normal. But in the case of this new therapy, some of the patients participating in the trial developed normal bone marrow.

    Researchers studied imetelstat in 33 patients atMayo Clinic and have now followed the first 22 patients for more than six months. Among these 22 patients, two achieved complete remissions and three partial remission, including reversal of bone marrow fibrosisin four of the five patients.

  • lws2000 lws2000 Jul 6, 2014 11:06 AM Flag

    From END$$$----"I agree that Gern got a big lift from the MC, but right now I don't think there is anything more that the MC can or will do to help Gern get the FDA to lift the hold on Gern. That is Gern's job. GERN fate is in their own hands now, and it must be the one to move Imetalstat forward. It is not a question of the MC succeeding in larger trials. The ultimate question is whether IMETALSTAT succeeds."------$$$

    ALL---Without Mayo, Geron could be a failed company, IMO. BLACK$$$ is correct, that we know very little about GERN-Mayo agreements, and who has the most control. Mayo works well with the FDA, and has decades of experience doing so. Mayo has that level of trust that can only be formed with the test of time. Geron is wise to let Mayo lead the parade.

    Of course, Geron benefits when Mayo succeeds. I think we are all saying about the same thing with somewhat different emphases. Imetelstat works and is safe.

  • lws2000 lws2000 Jul 6, 2014 12:09 AM Flag

    I am talking about practical control. Geron is still under a hold, while Mayo's trials continue. The only organization with data and updated results is Mayo, plus they have the FDA's ear. Geron , in terms of their hold being lifted, and eventually a higher stock price, can only get there if Mayo succeeds. Geron, logically, is aware of what Mayo is doing, and has no reason to object. (Mayo is doing a good job.)

    At this point in time, only Mayo matters. Geron is totally dependent on Mayo for their future. So far Mayo has come through for Geron beyond anyone's expectations. Imetelstat's future looks bright, but the corporate structure going forward is unknown to the public. Mayo, Geron, the FDA, and an unknown partner or owner are all parts of the equation. The medical successes, that are public, are encouraging.

  • I believe that all important decisions, concerning Imetelstat, are being made between Mayo Clinic and the FDA. Geron, as a somewhat tarnished company, is an observer (like the rest of us). Mayo Clinic, apparently, knows most of the answers, but is being very careful, since there is so much medical science and the future of cancer research here (genetics, telomeres, cancer stemcells, Nobel Prizes, etc.). Mayo (and their staff) is a primary beneficiary (with these successes), as a leader in cancer research. I believe Mayo is in control, and the future of Imelelstat is bright. The most important fact, I believe, is that the positive news (from Dr. Tefferi and Mayo trials) overwhelms any negative news (very little).

  • Message board is blank.

  • Reply to

    Geron Stock

    by frhornwoman Jul 2, 2014 9:38 AM
    lws2000 lws2000 Jul 4, 2014 3:56 PM Flag

    Logic would suggest that Seeking Alpha (more influence than the Wall Street Journal in moving stock prices according to Purdue U.) is correct, and Geron's stock is about to "explode". Black### points out that Geron has little or nothing to do with logic. Hopefully that is changing with a more informed group of investors.

  • lws2000 lws2000 Jul 3, 2014 7:07 PM Flag

    One would think that this is the unofficial end of all holds related to liver side effects. The official release cannot be far behind.

  • lws2000 lws2000 Jul 3, 2014 12:24 PM Flag

    You are going in the wrong direction.

    Sentiment: Strong Buy

  • Reply to

    The reason Geron is stalled.

    by woofs_a_lot Jul 3, 2014 10:32 AM
    lws2000 lws2000 Jul 3, 2014 12:05 PM Flag

    The market forces have controlled this stock by various techniques that are found in technical analysis. That is changing because Mayo Clinic has been so successful, and is also an important influence in medical science, that will not be ignored by the FDA. This stock will explode because the fundamentals will dwarf the technical factors (channel trading, etc.). Cancer remissions and cures always demand a premium. The "stall" is ending.

  • Reply to

    Seeking Alpha

    by blackmarango Jul 2, 2014 4:35 PM
    lws2000 lws2000 Jul 2, 2014 5:12 PM Flag

    I don't have the link in front of me. I read that a comprehensive study at Purdue University showed that Seeking Alpha had more influence in moving markets than the Wall Street Journal. Did anyone else see that article?

  • Why does the GOP think women are too dumb to vote for their bodies' needs and their children's safety? At least Target is getting the message.

    "Target recognised that moms are a powerful customer base and political force - and you can respect the Second Amendment and the safety of customers at the same time."

  • Reply to

    Back to 2.90 price before SA article bs

    by herecmdabearszzzzs Jul 2, 2014 10:38 AM
    lws2000 lws2000 Jul 2, 2014 10:54 AM Flag

    The SA article was a catalyst for the small spike in the stock price, but opened the eyes of many investors around the world. The trend line is up, with the usual gyrations along the way. Get smart and accumulate during the oscillations.

  • lws2000 lws2000 Jul 2, 2014 9:28 AM Flag

    I keep looking for medical and scientific negatives from the published contributions of Mayo Clinic (primarily Dr. Tefferi), and I can not find much. No cancer drug is perfect, and all drugs have some side effects or patients where the drug does not work. Considering the power of this drug (unheard of remissions with reasonable safety), the negatives are minimal.

    To me, on a scale of 1 to 10, this looks like about an 8 or better. The market-makers gyrations will eventually go away as the dominant force, and Mayo Clinic's successful trials (good medicine, good science) will send the stock price trending upward for a considerable time. Time is on Geron's side, because they have a powerful advocate in Mayo, and a Nobel Prize in the Imetelstat science, plus a solid balance sheet and potential deep pocketed partners in the wings.

MSFT
42.09+0.40(+0.97%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.